|
Vortioxetine versus placebo for treatment of major depressive disorder
|
Masoud Behzadifar   , Hamidreza Dehghan , Kourosh Saki , Kourosh Sayehmiri , Meysam Behzadifar , Ali Akbari Sari |
| 4. Department of Health Management and Economics, Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran , masoudbehzadifar@gmail.com |
|
|
Abstract: (4623 Views) |
| Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics.
Materials and methods: A comprehensive literature search (PubMed, the Cochrane library, Scopus, CRD and HTA Database in January 2015) was performed, containing controlled clinical trials that vortioxetine 10 mg/d versus placebo in adults with major depressive disorder.
Results: Six controlled clinical trials were included in this meta-analysis. There was a significant difference between the vortioxetine 10 mg/d versus placebo in the Montgomery–Åsberg Depression Rating Scale (MADRS) (P value <0.00001). The results of pooled analysis for diarrhea, dry mouth, dizziness, headache and nausea were also significant (P value <0.00001). Vortioxetine 10 mg/d versus placebo showed a significant difference for nausea, but no significant differences were observed for the other five adverse effects.
Conclusion: Therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo. |
|
| Keywords: Vortioxetine 10 mg/d, Systematic Review, Meta-analysis, Major Depressive Disorder |
|
|
Full-Text [PDF 780 kb]
(1362 Downloads)
|
Type of Study: Review Article |
Subject:
Psychology
Received: 2015/03/11 | Accepted: 2015/08/16 | Published: 2015/09/9
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
